### Analysis

The earnings call for Amgen Inc. revealed strong quarterly results, with revenue growth of 12% driven by volume increases and the continued success of innovative products such as sotorasib and tezepelumab. The company also highlighted positive developments in its biosimilar and inflammation portfolios. However, the call also addressed the potential impact of the COVID-19 pandemic on future performance, particularly in the fourth quarter and beyond. The company's guidance for the remainder of 2020 was narrowed due to the uncertainty created by the recent resurgence of COVID-19 infections globally. Despite these challenges, management expressed optimism about the company's long-term prospects, driven by its innovative pipeline and strategic focus on growth.

### Conclusion

The short-term impact on Amgen's stock price is likely to be neutral to slightly positive, given the strong quarterly results and the company's optimistic outlook. The narrowing of guidance due to COVID-19 may cause some short-term volatility, but the overall positive performance and management's strategic vision are likely to support the stock price in the coming weeks. The numeric rating is:

0